UK Lags Behind EU Counterparts In Uptake Of Oncology Biomarker Testing

Research reveals that the uptake of diagnostic testing amongst cancer patients in the UK trails behind that of other Western European markets. The data, which comes from Ipsos Healthcare's Global Oncology Monitor, shows that across three of the most highly-researched oncology biomarkers - HER2, KRAS and EGFR mutation - the proportion of relevant patients undergoing genetic testing in the UK was behind the EU4 average for the past few years. In fact, more often than not, the UK trailed each of the four individual markets...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news